Meyka Pro banner
Precigen, Inc.

Precigen, Inc. (PGEN) Stock Overview

Explore Precigen, Inc.’s financial performance, market position, analyst ratings, and future outlook.

PGENNASDAQ
HealthcareBiotechnology
$7.70
$0.08(1.03%)
U.S. Market opens in 10h 44m

Precigen, Inc. (PGEN)

Meyka AI Score

Z

Key Financials

Market Cap2.7B
P/E Ratio-6.82
EPS (TTM)$-1.10
ROE-4.98%
Fundamental Analysis

AI Price Forecasts

1 Month$6.20
3 Months$7.38
1 Year Target$7.00

PGEN Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Precigen, Inc. (NASDAQ: PGEN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Precigen, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of PGEN on the NASDAQ shows an RSI of 64.78, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $7.00 for the NASDAQ listing.

Key metrics behind Precigen, Inc.'s NASDAQ-traded stock include a P/E ratio of -6.82 and a market capitalization of 2.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of PGEN on the NASDAQ.

Price Performance (NASDAQ: PGEN)

1-Day Change
-1.03%
5-Day Change
10.00%
1-Month Change
6.94%
3-Month Change
43.12%
6-Month Change
134.76%
Year-to-Date (YTD) Change
84.21%
1-Year Change
100.00%
3-Year Change
450.00%
5-Year Change
41.80%
All-Time (Max) Change
-67.39%

Contact Information

301 556 9900
20374 Seneca Meadows Parkway, Germantown, MD, 20876

Company Facts

1,600 Employees
IPO DateAug 8, 2013
CountryUS
Actively Trading

Frequently Asked Questions